Linan Song, David Hanlon, Dipika Gemani, Adam Shepro, Andreas Jeromin, Aarti Chawla, and Michael Catania
Several investigations have reported that traumatic brain injury (TBI) is a significant risk factor for neurodegenerative diseases. There is a widely recognized need for sensitive, accurate and rapid blood-based biomarker assays to supplement computed tomography (CT) scans and functional assessments commonly used for acute diagnosis of TBI. Here we developed digital ELISA assays using single molecule array (Simoa) technology for ultrasensitive measurement of serum glial fibrillary acid protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1), respectively.
Share this page